Muteins of human lipocalin 2 with affinity for glypican-3 (gpc-3)
AssigneePieris AG
InventorsGabriele Matschiner, Andreas Hohlbaum, Kristian Jensen
Life of this patent
Estimating the term…
Abstract
Described are specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins include muteins of a lipocalin protein, such as lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.
Claims21
1-63. (canceled)
A mutein of hNGAL comprising amino acid substitutions at nine or more of any of the sequence positions corresponding to sequence positions 36, 40, 41, 49, 52, 68, 70, 72, 73, 77, 79, 81, 96, 100, 103, 106, 125, 127, 132, and 134 of the linear polypeptide sequence of hNGAL (SEQ ID NO:
- 27), wherein the mutein is capable of binding glypican-3 (GPC3) with an affinity by a KD of about 10 nM or lower.
Dependencies are inferred from the claim text.